DK0792162T3 - Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier - Google Patents

Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier

Info

Publication number
DK0792162T3
DK0792162T3 DK95933826T DK95933826T DK0792162T3 DK 0792162 T3 DK0792162 T3 DK 0792162T3 DK 95933826 T DK95933826 T DK 95933826T DK 95933826 T DK95933826 T DK 95933826T DK 0792162 T3 DK0792162 T3 DK 0792162T3
Authority
DK
Denmark
Prior art keywords
mycobacteria
gram
positive bacteria
antibodies
effects
Prior art date
Application number
DK95933826T
Other languages
English (en)
Inventor
Richard J Ulevitch
Peter S Tobias
Jerome Pugin
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK0792162T3 publication Critical patent/DK0792162T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK95933826T 1994-09-16 1995-09-15 Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier DK0792162T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30793194A 1994-09-16 1994-09-16

Publications (1)

Publication Number Publication Date
DK0792162T3 true DK0792162T3 (da) 2006-03-27

Family

ID=23191790

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95933826T DK0792162T3 (da) 1994-09-16 1995-09-15 Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier

Country Status (9)

Country Link
US (3) US6168790B1 (da)
EP (1) EP0792162B1 (da)
JP (1) JP3892902B2 (da)
AT (1) ATE308994T1 (da)
CA (1) CA2200054C (da)
DE (1) DE69534601T2 (da)
DK (1) DK0792162T3 (da)
ES (1) ES2255708T3 (da)
WO (1) WO1996008272A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
AU6392996A (en) * 1995-06-19 1997-01-15 Sanna M. Goyert A method for inhibiting bacteremia and bacterial dissemination
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO2000042994A2 (en) * 1999-01-21 2000-07-27 North Shore-Long Island Jewish Research Institute Inhibition of bacterial dissemination
WO2001022085A1 (en) * 1999-09-17 2001-03-29 Mochida Pharmaceutical Co., Ltd. Method of fractional measurement of soluble cd14 protein
CA2404511A1 (en) * 2000-03-31 2001-10-04 Mochida Pharmaceutical Co., Ltd. Tlr/cd14 binding inhibitor
JPWO2002042333A1 (ja) * 2000-11-22 2004-03-25 持田製薬株式会社 Ｃｄ１４／ｔｌｒ結合阻害作用を有する抗ｃｄ１４モノクローナル抗体
US20040028651A1 (en) * 2001-03-29 2004-02-12 Karrupiah Muthumani Composition and methods of using hiv vpr
CN1564696A (zh) * 2001-10-05 2005-01-12 宾西法尼亚大学托管人 治疗和预防全身炎性反应综合症/败血症的药物组成和方法
WO2004103294A2 (en) * 2003-05-15 2004-12-02 Tanox, Inc. Methods and compositions for the prevention and treatment of sepsis
EP2668207A4 (en) 2011-01-24 2015-06-10 Univ Singapore MANNOSE-CAPTURED LIPOARABINOMANANE ANTIGEN-BINDING PROTEINS OBTAINED FROM ILLNESSIFYING MYCOBACTERIES
AU2018255489B2 (en) 2017-04-21 2024-06-13 Implicit Bioscience Limited CD 14 antagonist antibodies for treating neurodegenerative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2744130B2 (ja) * 1989-08-01 1998-04-28 スクリップス クリニック アンド リサーチ ファウンデーション 敗血症治療用組成物
US5436321A (en) * 1990-02-01 1995-07-25 The Rockefeller University Antibodies to the lipopolysaccharide bonding opsonin septin
ATE335072T1 (de) * 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung

Also Published As

Publication number Publication date
EP0792162A4 (en) 2003-03-19
CA2200054C (en) 2010-03-16
DE69534601D1 (de) 2005-12-15
US20010022969A1 (en) 2001-09-20
JPH10505839A (ja) 1998-06-09
ES2255708T3 (es) 2006-07-01
AU3633695A (en) 1996-03-29
US6168790B1 (en) 2001-01-02
EP0792162B1 (en) 2005-11-09
AU703169B2 (en) 1999-03-18
ATE308994T1 (de) 2005-11-15
US20030103969A1 (en) 2003-06-05
CA2200054A1 (en) 1996-03-21
EP0792162A1 (en) 1997-09-03
DE69534601T2 (de) 2006-08-03
JP3892902B2 (ja) 2007-03-14
WO1996008272A1 (en) 1996-03-21

Similar Documents

Publication Publication Date Title
DK0485430T3 (da) Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
DE69526340D1 (de) Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
DK0710228T3 (da) Hydraziner med N3S-konfiguration som radionuclidchelatorer
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
ATE168131T1 (de) T-cadherin-bindungsmolekül
ATE308994T1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
DE69324487D1 (de) Rezeptorbindende region des diphtherietoxius
RU94036748A (ru) Церамиды, способ их получения, композиция на их основе и способ гидратирующей обработки кожи или волос
RU2000105905A (ru) Способ лечения острого повреждения легких и способ лечения фиброза, моноклональное антитело, гибридома атсс нв12382
DK0620854T3 (da) Ekspression og oprensning af rekombinant opløselig vævsfaktor
ATE178053T1 (de) N2s2-chelatoren des hydrazino-typs
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
AU1378395A (en) Metal chelators
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
BG99074A (bg) Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
DK0445280T3 (da) Terapeutisk middel og fremgangsmåde til inhibering af vaskularisering af tumorer
ES2236692T3 (es) Un metodo para prevenir los efectos secundarios y la insensibilidad a los usos terapeuticos de toxinas.
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers
Moroz et al. Neutralization of Vipera palestinae hemorrhagin by antibody fragments
FI924278A0 (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner.
NZ329403A (en) Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L